SOUTHBOROUGH, MA – June 19, 2017 – Veristat, a full service Clinical Research Organization (CRO), announced today that Veristat and AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, have entered into a Preferred Provider Agreement (PPA).
Ranked as one of the Top 50 Fastest Growing Private Companies in Massachusetts
Veristat Strengthens its Clinical Operations, Medical and Regulatory Affairs Offerings
SOUTHBOROUGH, MA – November 07, 2016 – Veristat announced that it has appointed James (Jim) Roach, MD, FACP, FCCP as its new Chief Medical Officer to bolster the expansion of its clinical operations, medical and regulatory affairs offerings.
SOUTHBOROUGH, MA – November 01, 2016 – Veristat, a full service consultative Clinical Research Organization (CRO), announced today the formal launch of its Strategic Decision Consulting service offering to help pharmaceutical, biotechnology and medical device firms solve the unique and complex challenges they face throughout the development process.
Veristat, a full service Clinical Research Organization (CRO), announced today the signing of a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals Inc. (“Aegerion”), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Veristat has assisted Aegerion with US Food and Drug Administration, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years.
Veristat Continues To Be Recognized for Its Positive Impact & Company Growth
SOUTHBOROUGH, MA – August 17, 2016 – Veristat announced today that it has been recognized once again by Inc. Magazine as one of America’s fastest-growing private companies. Veristat debuted on the list in 2015.
Accelerates Hiring & Plans to Open Office in Raleigh-Durham, North Carolina